HOME ＞ 研究業績詳細
研究業績詳細
加藤 俊介（カトウ シュンスケ）
| 研究テーマ | がん関連遺伝子の機能解析、バイオマーカー研究 |
|---|---|
| 研究業績（論文） | Ancestry-, Sex-, and Age-Based Differences of Gene Alterations in NSCLC: From the Real-World Data of Cancer Genomic Profiling Tests. Miura K, Shukuya T, Greenstein R, Kaplan B, Wakelee H, Kurokawa K, Furuta K, Kato S, Suh J, Sivakumar S, Sokol ES, Carbone DP, Takahashi K. J Natl Compr Canc Netw. 2024 Aug 8:1-10. doi: 10.6004/jnccn.2024.7021. Online ahead of print. Identification of BRAF Inhibitor Resistance-associated lncRNAs Using Genome-scale CRISPR-Cas9 Transcriptional Activation Screening. Wen X, Han M, Hosoya M, Toshima R, Onishi M, Fujii T, Yamaguchi S, Kato S. Anticancer Res. 2024 Jun;44(6):2349-2358. doi: 10.21873/anticanres.17042. Pulmonary Erdheim-Chester Disease With BRAF-AGAP3 Fusion: Late-Onset Osteolytic Femoral Lesions Despite Long-Term Pulmonary Stabilization With Corticosteroid. Nishino K, Takagi T, Hayashi T, Kunimine S, Tsuchihashi H, Kato S, Takahashi K, Seyama K. Cureus. 2024 Mar 6;16(3):e55670. doi: 10.7759/cureus.55670. eCollection 2024 Mar. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing. Hasegawa N, Hayashi T, Niizuma H, Kikuta K, Imanishi J, Endo M, Ikeuchi H, Sasa K, Sano K, Hirabayashi K, Takagi T, Ishijima M, Kato S, Kohsaka S, Saito T, Suehara Y. Clin Orthop Relat Res. 2024 Mar 1;482(3):549-563. doi: 10.1097/CORR.0000000000002901. Epub 2023 Nov 28. Prevalence of psychological distress and associated factors among patients undergoing comprehensive genomic profiling testing: protocol for a multicentre, prospective, observational study. Matsuoka A, Fujimori M, Koyama T, Sato A, Mori K, Hirata M, Tanabe N, Nakachi K, Kato S, Okamoto H, Ogawa K, Komatsu H, Iwasaku M, Miyaji T, Uchitomi Y. BMJ Open. 2023 Nov 23;13(11):e072472. doi: 10.1136/bmjopen-2023-072472. Copy number loss of KDM5D may be a predictive biomarker for ATR inhibitor treatment in male patients with pulmonary squamous cell carcinoma. Ura A, Hayashi T, Komura K, Hosoya M, Takamochi K, Sato E, Saito S, Wakai S, Handa T, Saito T, Kato S, Suzuki K, Yao T; Tokyo Metropolitan Innovative Oncology Research Group (TMIG). J Pathol Clin Res. 2024 Jan;10(1):e350. doi: 10.1002/cjp2.350. Epub 2023 Nov 16. Genomic characterization of thymic epithelial tumors in a real-world dataset.Kurokawa K, Shukuya T, Greenstein RA, Kaplan BG, Wakelee H, Ross JS, Miura K, Furuta K, Kato S, Suh J, Sivakumar S, Sokol ES, Carbone DP, Takahashi K. ESMO Open. 2023 Oct;8(5):101627. doi: 10.1016/j.esmoop.2023.101627. Epub 2023 Sep 12. Long-term effect of letrozole on metastatic uterine smooth muscle tumors of uncertain malignant potential: A case report. Praben P, Kido H, Terao Y, Takagi T, Hayashi T, Naito T, Kato S. J Obstet Gynaecol Res. 2023 Aug 23. doi: 10.1111/jog.15777. Two-year crizotinib monotherapy induced durable complete response of pediatric ALK-positive inflammatory myofibroblastic tumor.Kaino A, Niizuma H, Katayama S, Irie M, Nakano T, Sato D, Saito T, Kato S, Suehara Y, Sasahara Y, Kikuchi A. Pediatr Blood Cancer. 2023 Aug;70(8):e30330. doi: TP53 Signature Score Predicts Prognosis and Immune Response in Triple-negative Breast Cancer. Onishi M, Yamaguchi S, Wen X, Han M, Kido H, Aruga T, Horiguchi SI, Kato S. Anticancer Res. 2023 Apr;43(4):1731-1739. Effectiveness of Changing the Class of Molecularly Targeted Agent after Disease Progression during Initial Molecularly Targeted Therapy for Luminal Advanced/Metastatic Breast Cancer. Nakano S, Mibu A, Kato S, Yamaguchi S, Suzuki Y, Tanimura K, Sano M. J Nippon Med Sch. 2023 May 30;90(2):179-185. Establishment of preanalytical conditions for microRNA profile analysis of clinical plasma samples. Suzuki K, Yamaguchi T, Kohda M, Tanaka M, Takemura H, Wakita M, Tabe Y, Kato S, Nasu M, Hashimoto T, Mine S, Serizawa N, Tomishima K, Nagahara A, Matsuda T, Yamaji T, Tsugane S, Saito Y, Daiko H, Yoshikawa T, Kato K, Okusaka T, Ochiya T, Yamamoto Y, Yotsui S, Yamamoto T, Yamasaki T, Miyata H, Yasui M, Omori T, Ohkawa K, Ikezawa K, Nakabori T, Sugimoto N, Kudo T, Yoshida K, Ohue M, Nishizawa T. PLoS One. 2022 Dec 14;17(12):e0278927. The MDM2 and CDKN2A Copy-number-variation Influence the TP53-signature-score in Wild-type TP53 Luminal Type Breast Cancer. Han M, Yamaguchi S, Onishi M, Fujii T, Hosoya M, Wen X, Kido H, Kato S. Anticancer Res. 2022 May;42(5):2277-2288. Characteristics of Li-Fraumeni Syndrome in Japan; A Review Study by the Special Committee of JSHT. Funato M, Tsunematsu Y, Yamazaki F, Tamura C, Kumamoto T, Takagi M, Kato S, Sugimura H, Tamura K. Cancer Sci . 2021 May 1;112(7):2821-2834. NTRK fusion in Japanese colorectal adenocarcinomas. Yamashiro Y, Kurihara T, Hayashi T, Suehara Y, Yao T, Kato S, Saito T.Sci Rep. 2021 Mar 11;11(1):5635. Tumour-Agnostic Therapy for Pancreatic Cancer and Biliary Tract Cancer. Kato S. Diagnostics (Basel). 2021 Feb 6;11(2):252 A Novel Diagnostic System to Evaluate Epidermal Growth Factor Receptor Impact as a Prognostic and Therapeutic Indicator for Lung Adenocarcinoma. Takakuwa K, Mogushi K, Han Min, Fujii T, Hosoya M, Yamanami A, Akita T, Yamashita C, Hayashida T, Kato S, Yamaguchi S. Sci Rep. 2020 Apr 10;10(1):6214. Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology. Naito Y, Mishima S, Akagi K, Igarashi A, Ikeda , Okano S, Kato S, Takano T, Tsuchihara K, Terashima K, Nishihara H, Nishiyama H, Hiyama E, Hirasawa A, Hosoi H, Maeda O, Yatabe Y, Okamoto W, Ono S, Kajiyama H, Nagashima F, Hatanaka Y, Miyachi M, Kodera Y, Yoshino T, Taniguchi H. Int J Clin Oncol. 2020 Mar;25(3):403-417. Multicenter experience with large panel next-generation sequencing in patients with advanced solid cancers in Japan. Kato S, Hayashi T, Suehara Y, Hamanoue H, Yamanaka S, Ichikawa Y, Higurashi T, Ohashi K, Yamaguchi S, Nozaki Y, Terao Y, Saito T, Yao T, Nakajima A, Syed A, Zehir A, Ladanyi, M, Kato S. Jpn J Clin Oncol.2019 Feb 1;49(2):174-182. Molecular and clinical features of the TP53 signature gene expression profile in early-stage breast cancer.Yamaguchi S, Takahashi S, Mogushi K, Izumi Y, Nozaki Y, Nomizu T, Kakugawa Y, Ishida T, Ohuchi N, Ishioka C, Kato S. Oncotarget. 2018;9(18):14193-14206. Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients. Kageyama SI, Nihei K, Karasawa K, Sawada T, Koizumi F, Yamaguchi S, Kato S, Hojo H, Motegi A, Tsuchihara K, Akimoto T. Oncotarget. 2018 Apr 10;9(27):19368-19378. Intermittent Withdrawal of Oxaliplatin for Alleviating Neurotoxicity during Oxaliplatin-Based Chemotherapy for Japanese Patients with Inoperable or Metastatic Colorectal Cancer: A Phase 2 Multicenter Study. Kato S, Imai H, Gamoh M, Takahata T, Ohori H, Yasuda K, Niitani T, Murakawa Y, Amagai K, Isobe H, Shindo Y, Kuroki M, Sakamoto Y, Shimodaira H, Yoshioka T, Ishioka C. Tohoku J Exp Med. 2018;245(1):21-28. Identification and characterization of a novel adenomatous polyposis coli mutation in adult pancreatoblastoma. Oncotarget. Yamaguchi S, Fujii T, Izumi Y, Fukumura Y, Han M, Yamaguchi H, Akita T, Yamashita C, Kato S, Sekiya T. 2018 Jan 6;9(12):10818-10827. Large skin ulcer due to a subcutaneous orthopedic implant after bevacizumab therapy: A case report. Suehara Y, Osawa H, Kubota D, Kato S, Akaike K, Toda Ishii M, Tanabe Y, Mukaihara K, Kim Y, Takagi T, Saito T, Kaneko K.. JBJS Case Connect, 2016 Aug 24; 6 (3): e70 . https://doi.org/10.2106/JBJS.CC.15.00281 A case report of using nivolumab for a malignant melanoma patient with rheumatoid arthritis. Shun-Ichiro kageyama,Shigeo Yamaguchi,Shin Ito,Yoshiyuki Suehara,Tsuyoshi Saito,Keisuke Akaike,Kayo Miura,Shunsuke Kato. International Cancer Conference Journal:23 July 2016 e-ISSN2192-3183 An analysis of the relationship between metastases and cachexia in lung cancer patients. Shiono M, Huang K, Downey RJ, Consul N, Villanueva N, Beck K, Fenn K, Dietz D, Yamaguchi T, Kato S, Divgi C, Kalinsky K, Wei Y, Zhang Y, Borczuk AC, Inoue A, Halmos B, Acharyya S. Cancer Med. 2016 Aug 3. doi: 10.1002/cam4.841. Synthetic lethal interaction of CDK inhibition and autophagy inhibition in human solid cancer cell lines. Okada Y, Kato S, Sakamoto Y, Oishi T, Ishioka C. Oncol Rep. 2017 Jul;38(1):31-42. The Era of Personalized Cancer Treatments Kato S. Juntendo Medicine (May 11, 2016) Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology. Shibata H, Kato S, Sekine I, Abe K, Araki N, Iguchi H, Izumi T, Inaba Y, Osaka I, Kato S, Kawai A, Kinuya S, Kodaira M, Kobayashi E, Kobayashi T, Sato J, Shinohara N, Takahashi S, Takamatsu Y, Takayama K, Takayama K, Tateishi U, Nagakura H, Hosaka M, Morioka H, Moriya T, Yuasa T, Yurikusa T, Yomiya K, Yoshida M. ESMO Open. 2016 Mar 16;1(2):e000037. eCollection 2016. Review. Gene-expression profiles correlate with the efficacy of anti-EGFR therapy and chemotherapy for colorectal cancer. Inoue M, Takahashi S, Soeda H, Shimodaira H, Watanabe M, Miura K, Sasaki I, Kato S, Ishioka C. Int J Clin Oncol. 2015 May 20:20(6):1147-55 Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer. Watanabe G, Ishida T, Furuta A, Takahashi S, Watanabe M, Nakata H, Kato S, Ishioka C, Ohuchi N. Am J Surg Pathol. 2015 Aug;39(8):1026-34. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801). Soeda H, Shimodaira H, Gamoh M, Ando H, Isobe H, Suto T, Takahashi S, Kakudo Y, Amagai K, Mori T, Watanabe M, Yamaguchi T, Kato S, Ishioka C. Oncology. 2014;87(1):7-20. KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin-or irinotecan-based treatment. Soeda H, Shimodaira H, Watanabe M, Suzuki T, Gamo M, Takahashi M, Komine K, Kato S, Ishioka C. Molecular and Clinical Oncology 2: 356-362, 2014 Upper Arm Central Venous Port Implantation: A 6-Year Single Institutional Retrospective Analysis and Pictorial Essay of Procedures for Insertion. Shiono M, Takahashi S, Kakudo Y, Takahashi M, Shimodaira H, Kato S, Ishioka C. PLoS One. 2014 Mar 10;9(3):e91335. doi: 10.1371/journal.pone.0091335. eCollection 2014 High throughput RNAi screening identifies ID1 as a synthetic sick/lethal gene interacting with the common TP53 mutation R175H. Imai H, Kato S, Sakamoto Y, Kakudo Y, Shimodaira H, Ishioka C. Oncol Rep. 2014 Mar;31(3):1043-50. doi: 10.3892/or.2013.2953. Epub 2013 Dec 30. |
| 研究者 | 教育活動 |